Tiziana Life Sciences completes Phase 2a intranasal foralumab MS trial enrollment
Tiziana Life Sciences (NASDAQ:TLSA) announced that the final patient has completed the final visit in its Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).










